

Rapidexon 2 mg/ml solution for injection

GHS Safety Data Sheet (Conforms to Regulation (EC) No 1907/2006, Article 31.)

Issue Date: 27-Nov-2012

Version No: 2.1.1.1

Page 1 of 6

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

Rapidexon 2 mg/ml solution for injection

PRODUCT USE

Used according to manufacturer's directions.

SUPPLIER

Company: Eurovet Animal Health BV

Address: Handelsweg 25
5531 AE Bladel
Netherlands

Telephone: +31 497 544 300

Fax: +31 497 544 302

Section 2 - HAZARDS IDENTIFICATION



EMERGENCY OVERVIEW

HAZARD

WARNING

H317 May cause an allergic skin reaction.

PRECAUTIONARY STATEMENTS

Prevention

Code

P261

Phrase

Avoid breathing dust/fume/gas/mist/vapours/spray.

P272

Contaminated work clothing should not be allowed out of the workplace.

P280

Wear protective gloves/protective clothing/eye protection/face protection.

Response

Code

P302+P352

Phrase

IF ON SKIN: Wash with plenty of soap and water.

P333+P313

If skin irritation or rash occurs: Get medical advice/attention.

P363

Wash contaminated clothing before reuse.

Disposal

Code

P501

Phrase

Dispose of contents/container to ...

Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

Composition:

Contains per ml:

2 mg dexamethasone (as dexamethasone sodium phosphate), CAS RN 2392-39-4

Rapidexon 2 mg/ml solution for injection

GHS Safety Data Sheet (Conforms to Regulation (EC) No 1907/2006, Article 31.)

Issue Date: 27-Nov-2012

Version No: 2.1.1.1

Page 2 of 6

Section 4 - FIRST AID MEASURES

SWALLOWED

- Immediately give a glass of water.
- First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor.

SKIN

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- In case of accidental self-injection, seek medical advice immediately and show the package leaflet to the physician.
- People with known hypersensitivity to the active substance or any of the excipients should avoid contact with the veterinary medicinal product.

INHALED

- If fumes, aerosols or combustion products are inhaled remove from contaminated area.
- Other measures are usually unnecessary.

NOTES TO PHYSICIAN

Treat symptomatically.

Section 5 - FIRE FIGHTING MEASURES

EXTINGUISHING MEDIA

- There is no restriction on the type of extinguisher which may be used.
- Use extinguishing media suitable for surrounding area.

FIRE/EXPLOSION HAZARD

- Non combustible.
- Not considered a significant fire risk, however containers may burn.

FIRE INCOMPATIBILITY

- None known.
-

Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS

- Clean up all spills immediately.
- Avoid breathing vapours and contact with skin and eyes.
- Control personal contact with the substance, by using protective equipment.
- Contain and absorb spill with sand, earth, inert material or vermiculite.

MAJOR SPILLS

Moderate hazard.

- Clear area of personnel and move upwind.
- Alert Fire Brigade and tell them location and nature of hazard.
- Wear breathing apparatus plus protective gloves.
- Prevent, by any means available, spillage from entering drains or water courses.

Personal Protective Equipment advice is contained in Section 8 of the MSDS.

Rapidexon 2 mg/ml solution for injection

GHS Safety Data Sheet (Conforms to Regulation (EC) No 1907/2006, Article 31.)

Issue Date: 27-Nov-2012

Version No: 2.1.1.1

Page 3 of 6

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- Pregnant women should not handle this veterinary medicinal product

SUITABLE CONTAINER

- Packing as supplied by manufacturer.
- Check all containers are clearly labelled and free from leaks.

STORAGE INCOMPATIBILITY

- None known.

STORAGE REQUIREMENTS

- Store in original containers.
- Keep containers securely sealed.
- Store away from incompatible materials and foodstuff containers.
- Do not store above 25°C.
- Do not freeze.
- Keep vial in outer container.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

The following materials had no OELs on our records:

- dexamethasone sodium phosphate: CAS:2392- 39- 4

PERSONAL PROTECTION

RESPIRATOR

- Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

OTHER

- Overalls.
- P.V.C. apron.
- Barrier cream.
- Skin cleansing cream.

ENGINEERING CONTROLS

No data for this material.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE

Clear liquid stored in colourless glass vials with a bromobutyl rubber stopper and secured with an aluminium cap.

PHYSICAL PROPERTIES

Liquid.

Rapidexon 2 mg/ml solution for injection

GHS Safety Data Sheet (Conforms to Regulation (EC) No 1907/2006, Article 31.)

Issue Date: 27-Nov-2012

Version No: 2.1.1.1

Page 4 of 6

State	Liquid
pH (as supplied)	7.0- 8.1

Section 10 - CHEMICAL STABILITY AND REACTIVITY INFORMATION

CONDITIONS CONTRIBUTING TO INSTABILITY

- Presence of incompatible materials.
- Product is considered stable.
- Hazardous polymerisation will not occur.

For incompatible materials - refer to Section 7 - Handling and Storage.

Section 11 - TOXICOLOGICAL INFORMATION

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

EYE

- Although the liquid is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort characterised by tearing or conjunctival redness (as with windburn).

SKIN

- The material is not thought to produce adverse health effects or skin irritation following contact (as classified by EC Directives using animal models).
Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.
- Open cuts, abraded or irritated skin should not be exposed to this material.
- Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

CHRONIC HEALTH EFFECTS

- There is limited evidence that, skin contact with this product is more likely to cause a sensitisation reaction in some persons compared to the general population.
Substance accumulation, in the human body, may occur and may cause some concern following repeated or long-term occupational exposure.
There is limited evidence that, skin contact with this product is more likely to cause a sensitisation reaction in some persons compared to the general population.

TOXICITY AND IRRITATION

- No significant acute toxicological data identified in literature search.

Section 12 - ECOLOGICAL INFORMATION

No data.

Rapidexon 2 mg/ml solution for injection

GHS Safety Data Sheet (Conforms to Regulation (EC) No 1907/2006, Article 31.)

Issue Date: 27-Nov-2012

Version No: 2.1.1.1

Page 5 of 6

Ecotoxicity

Ingredient	Persistence: Water/Soil	Persistence: Air	Bioaccumulation	Mobility
dexamethasone	No Data Available	No Data Available	No Data Available	No Data Available
sodium phosphate	No Data Available	No Data Available	No Data Available	No Data Available

Section 13 - DISPOSAL CONSIDERATIONS

No data for this material.

■ According to the European Waste Catalogue, Waste Codes are not product specific but application specific. Waste Codes should be assigned by the User based on the application in which the product is used.

Section 14 - TRANSPORTATION INFORMATION

HAZCHEM:

None

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: ADR, IATA, IMDG

Section 15 - REGULATORY INFORMATION

ANNEX I of Directive 67/548/EEC

benzyl alcohol	603- 057- 00- 5
sodium hydroxide	011- 002- 00- 6

RISK

Risk Codes	Risk Phrases
R33?	■ Cumulative effects may result following exposure*.
R43?	■ Possible skin sensitiser*.

SAFETY

Safety Codes	Safety Phrases
S23	■ Do not breathe gas/ fumes/ vapour/ spray.
S24	■ Avoid contact with skin.

REGULATIONS

No data for Rapidexon 2 mg/ml solution for injection

This safety data sheet is in compliance with the following EU legislation and its adaptations – as far as applicable - : 67/548/EEC, 1999/45/EC, 98/24/EC, 92/85/EEC, 94/33/EC, 91/689/EEC, 1999/13/EC, Regulation (EU) No 453/2010, Regulation (EC) No 1907/2006, Regulation (EC) No 1272/2008, and their amendments.

Rapidexon 2 mg/ml solution for injection

GHS Safety Data Sheet (Conforms to Regulation (EC) No 1907/2006, Article 31.)

Issue Date: 27-Nov-2012

Version No: 2.1.1.1

Page 6 of 6

Section 16 - OTHER INFORMATION

■ The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings.

■ For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

EN 16 Personal eye-protection

EN 340 Protective clothing

EN 374 Protective gloves against chemicals and micro-organisms

EN 13832 Footwear protecting against chemicals

EN 133 Respiratory protective devices.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from Eurovet Animal Health B.V.

Issue Date: 27-Nov-2012

Print Date: 5-Feb-2013